ANVISA guidelines for two-stage design [Two-Stage / GS Designs]

posted by ElMaestro  – Belgium?, 2020-02-12 08:27 (226 d 08:14 ago) – Posting: # 21162
Views: 3,212

Hi MS,

» Art.75. For two-stage studies, the following should be noted: It is acceptable to use a two-stage approach to demonstrate bioequivalence based on ignorance of the intra-individual variability of the drug;


Ermmm...... WHAT???? :-D:party:

I could be wrong, but...

Best regards,
ElMaestro

R's base package has 274 reserved words and operators, along with 1761 functions. I can use 18 of them (about 14 of them properly). I believe this makes me the Donald Trump of programming.

Complete thread:

Activity
 Admin contact
21,075 posts in 4,394 threads, 1,468 registered users;
online 2 (0 registered, 2 guests [including 1 identified bots]).
Forum time: Friday 17:42 CEST (Europe/Vienna)

If you think it’s simple,
then you have misunderstood the problem.    Bjarne Stroustrup

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5